168 related articles for article (PubMed ID: 38099944)
41. Mediators between canagliflozin and renoprotection vary depending on patient characteristics: Insights from the CREDENCE trial.
Doi Y; Hamano T; Yamaguchi S; Sakaguchi Y; Kaimori JY; Isaka Y
Diabetes Obes Metab; 2023 Oct; 25(10):2944-2953. PubMed ID: 37385955
[TBL] [Abstract][Full Text] [Related]
42. Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS.
Koshino A; Schechter M; Sen T; Vart P; Neuen BL; Neal B; Arnott C; Perkovic V; Ridker PM; Tuttle KR; Hansen MK; Heerspink HJL
Diabetes Care; 2022 Nov; 45(11):2644-2652. PubMed ID: 36134918
[TBL] [Abstract][Full Text] [Related]
43. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).
Mahaffey KW; Neal B; Perkovic V; de Zeeuw D; Fulcher G; Erondu N; Shaw W; Fabbrini E; Sun T; Li Q; Desai M; Matthews DR;
Circulation; 2018 Jan; 137(4):323-334. PubMed ID: 29133604
[TBL] [Abstract][Full Text] [Related]
44. Clinical efficacy and safety of canagliflozin combined with valsartan in the treatment of early and mid-stage diabetic nephropathy.
Ma D; Cao T
Minerva Surg; 2024 Jun; 79(3):368-370. PubMed ID: 38127437
[No Abstract] [Full Text] [Related]
45. Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis.
Zhou Z; Jardine MJ; Li Q; Neuen BL; Cannon CP; de Zeeuw D; Edwards R; Levin A; Mahaffey KW; Perkovic V; Neal B; Lindley RI;
Stroke; 2021 May; 52(5):1545-1556. PubMed ID: 33874750
[TBL] [Abstract][Full Text] [Related]
46. Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS programme and CREDENCE trial.
Yu J; Li J; Leaver PJ; Arnott C; Huffman MD; Udell JA; Perkovic V; Mahaffey KW; de Zeeuw D; Fulcher G; Matthews DR; Shaw W; Rosenthal N; Neal B; Figtree GA
Cardiovasc Res; 2022 Mar; 118(4):1103-1114. PubMed ID: 33826709
[TBL] [Abstract][Full Text] [Related]
47. Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program.
Yu J; Arnott C; Neuen BL; Heersprink HL; Mahaffey KW; Cannon CP; Khan SS; Baldridge AS; Shah SJ; Huang Y; Li C; Figtree GA; Perkovic V; Jardine MJ; Neal B; Huffman MD
ESC Heart Fail; 2021 Apr; 8(2):1482-1493. PubMed ID: 33595905
[TBL] [Abstract][Full Text] [Related]
48. Study of Angiopoietin-2 and vascular endothelial growth factor as markers of diabetic nephropathy onset in Egyptians diabetic patients with non-albuminuric state.
Aly MH; Arafat MA; Hussein OA; Elsaid HH; Abdel-Hammed AR
Diabetes Metab Syndr; 2019; 13(2):1623-1627. PubMed ID: 31336531
[TBL] [Abstract][Full Text] [Related]
49. Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function.
Neuen BL; Ohkuma T; Neal B; Matthews DR; de Zeeuw D; Mahaffey KW; Fulcher G; Desai M; Li Q; Deng H; Rosenthal N; Jardine MJ; Bakris G; Perkovic V
Circulation; 2018 Oct; 138(15):1537-1550. PubMed ID: 29941478
[TBL] [Abstract][Full Text] [Related]
50. The kidney and cardiovascular outcome trials.
Bloomgarden Z
J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
[TBL] [Abstract][Full Text] [Related]
51. Effects of Canagliflozin on Amino-Terminal Pro-B-Type Natriuretic Peptide: Implications for Cardiovascular Risk Reduction.
Januzzi JL; Xu J; Li J; Shaw W; Oh R; Pfeifer M; Butler J; Sattar N; Mahaffey KW; Neal B; Hansen MK
J Am Coll Cardiol; 2020 Nov; 76(18):2076-2085. PubMed ID: 33121714
[TBL] [Abstract][Full Text] [Related]
52. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial.
Neal B; Perkovic V; Matthews DR; Mahaffey KW; Fulcher G; Meininger G; Erondu N; Desai M; Shaw W; Vercruysse F; Yee J; Deng H; de Zeeuw D;
Diabetes Obes Metab; 2017 Mar; 19(3):387-393. PubMed ID: 28120497
[TBL] [Abstract][Full Text] [Related]
53. Extremes of both weight gain and weight loss are associated with increased incidence of heart failure and cardiovascular death: evidence from the CANVAS Program and CREDENCE.
Ferrannini G; Pollock C; Natali A; Yavin Y; Mahaffey KW; Ferrannini E
Cardiovasc Diabetol; 2023 Apr; 22(1):100. PubMed ID: 37120538
[TBL] [Abstract][Full Text] [Related]
54. Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure.
Tye SC; Jongs N; Coca SG; Sundström J; Arnott C; Neal B; Perkovic V; Mahaffey KW; Vart P; Heerspink HJL
Cardiovasc Diabetol; 2022 Sep; 21(1):194. PubMed ID: 36151557
[TBL] [Abstract][Full Text] [Related]
55. Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial.
Neuen BL; Oshima M; Perkovic V; Agarwal R; Arnott C; Bakris G; Cannon CP; Charytan DM; Edwards R; Górriz JL; Jardine MJ; Levin A; Neal B; De Nicola L; Pollock C; Rosenthal N; Wheeler DC; Mahaffey KW; Heerspink HJL
Eur Heart J; 2021 Dec; 42(48):4891-4901. PubMed ID: 34423370
[TBL] [Abstract][Full Text] [Related]
56. SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes.
Wheeler DC; James J; Patel D; Viljoen A; Ali A; Evans M; Fernando K; Hicks D; Milne N; Newland-Jones P; Wilding J;
Diabetes Ther; 2020 Dec; 11(12):2757-2774. PubMed ID: 32996085
[TBL] [Abstract][Full Text] [Related]
57. Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program.
Rådholm K; Figtree G; Perkovic V; Solomon SD; Mahaffey KW; de Zeeuw D; Fulcher G; Barrett TD; Shaw W; Desai M; Matthews DR; Neal B
Circulation; 2018 Jul; 138(5):458-468. PubMed ID: 29526832
[TBL] [Abstract][Full Text] [Related]
58. Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program.
Oshima M; Neal B; Toyama T; Ohkuma T; Li Q; de Zeeuw D; Heerspink HJL; Mahaffey KW; Fulcher G; Canovatchel W; Matthews DR; Perkovic V
J Am Soc Nephrol; 2020 Oct; 31(10):2446-2456. PubMed ID: 32694216
[TBL] [Abstract][Full Text] [Related]
59. Effects of canagliflozin on major adverse cardiovascular events by baseline estimated glomerular filtration rate: Pooled Hispanic subgroup analyses from the CANVAS Program and CREDENCE trial.
Weir MR; Gogate J; Damaraju CV; Correa-Rotter R; Mahaffey KW
Diabetes Obes Metab; 2022 Jan; 24(1):12-20. PubMed ID: 34463423
[TBL] [Abstract][Full Text] [Related]
60. The association of angiogenic factors and chronic kidney disease.
Anderson CE; Hamm LL; Batuman G; Kumbala DR; Chen CS; Kallu SG; Siriki R; Gadde S; Kleinpeter MA; Krane NK; Simon EE; He J; Chen J
BMC Nephrol; 2018 May; 19(1):117. PubMed ID: 29783932
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]